Publisher(s): China Academic Journals (CD Edition) Electronic Publishing House Co., Ltd.
ISBN: ISBN 978-7-499-00969-1 pdf
First Published: 2020.11.23
Discipline(s): Medicine & Public Health
Price: $49 (for individuals) (中国大陆地区个人用户点此直接购买)
Institution users and community members, please click here to contact us.
Diabetes (Western Medicine), as part of the China’s Medicine Progress Series, has 27 research articles regarding the application of western medical approaches in the treatment and care of diabetes. The included articles are recommended by the editorial boards of the journals in which they were first published, covering mechanism, clinical, and nursing studies and fully demonstrating the cutting-edge progress in the treatment of diabetes in China, with scientific methodological support and objective conclusions. The original papers were published in Chinese, and this book is a compilation of selections in English version.
JIANG Xiaoying, a second-tier professor and doctoral supervisor, was once the dean of School of Nursing, Fujian Medical University and is now the president of Chinese Journal of Nursing. He is granted the special government allowance by the State Council.
1. Comparison of the Efficacy and Safety between DPP-4 Inhibitors and GLP-1 Analogues for Treatment of Type 2 Diabetes Mellitus: A Meta-analysis
Chinese Pharmaceutical Journal,Part 2: Clinical Study,Vol 51,No. 01
OBJECTIVE To systematically review the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors versus glucagon like peptide-1 (GLP-1) receptor agonists for type 2 diabetes mellitus (T2DM). METHODS Databases including EMbase, PubMed, The Cochrane Library, Clinical Trial, CBM, CNKI and WanFang Data, were searched electronically for randomized controlled trials (RCTs) of DPP-4 inhibitors versus GLP-1 receptor agonists for T2DM up to December 2015. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then Meta-analysis was performed using RevMan 5.3 software. RESULTS A total of 13 RCTs were included. The results of Meta-analysis showed that compared with DPP-4 inhibitors, GLP-1 receptor agonists were more effective in reducing the levels of fasting plasma glucose [MD = 0.93, 95% CI (0.48, 1.38), P < 0.0001] and glycated hemoglobin [MD = 0.53, 95% CI (0.34, 0.73), P < 0.000 01] and BMI [MD = 1.53, 95% CI (0.83, 2.22), P < 0.001]. However, DPP-4 inhibitors were more effective than GLP-1 receptor agonists in the reducing the 2-hour postprandial blood glucose level. And GLP-1 receptor agonists were more prone to cause gastrointestinal adverse reactions than DPP-4 inhibitors [RR = 0.44, 95% CI (0.33, 0.59), P < 0.0001]. CONCLUSION GLP-1 receptor agonists are superior to DPP-4 inhibitors in controlling the fasting plasma glucose and glycated hemoglobin levels and reducing the body weight of T2DM patients, while DPP-4 inhibitors have better efficacy in reducing 2-hour postprandial blood glucose level, with better tolerability.
2. A Prospective Randomized Controlled Study of Chronic Disease Management Led by Endocrinology Clinical Pharmacists in Patients with Type 2 Diabetes
Chinese Pharmaceutical Journal,Part 2: Clinical Study,Vol 54,No. 02
OBJECTIVE To evaluate the effect of chronic disease management led by endocrinology clinical pharmacists on the clinical indexes and medication self-management ability of patients with type 2 diabetes mellitus through a randomized controlled study. METHODS The study included 67 inpatients with type 2 diabetes. Clinical pharmacists conducted systematic education of chronic diseases on the patients. On the principle of allocation concealment, the patients were randomly divided into intervention group and control group when discharged. The clinical pharmacists followed the patients in the intervention group regularly, and instructed them to improve life style and adjust pharmaco therapy regimen according to the clinical indicators. After 3 months and 6 months, the clinical indicators were determined and self-management reassessed. RESULTS In the intervention group, the absolute value, improvement magnitude, control rate of glycosylated hemoglobin, the improvement of low density lipoprotein, the absolute value, improvement, control rate of systolic blood pressure and score of knowledge about medicine and compliance were all better than those of the control group ( P < 0.05). CONCLUSION The chronic disease management led by clinical pharmacists can improve the treatment effect of type 2 diabetes patients.